• 1
    Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol 2009;31:283-307.
  • 2
    Dhirapong A, Yang GX, Nadler S, Zhang W, Tsuneyama K, Leung P, et al. Therapeutic effect of CTLA4-Ig on a murine model of primary biliary cirrhosis. Hepatology 2013;57:708-715.
  • 3
    Beuers UH, Boberg KM, Chapman RW, Chazouillères O, Invernizzi P, Jones DE, et al. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-267.
  • 4
    Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006;177:1655-1660.
  • 5
    Irie J, Wu Y, Wicker LS, Rainbow D, Nalesnik MA, Hirsch R, et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 2006;203:1209-1219.
  • 6
    Salas JT, Banales JM, Sarvide S, Recalde S, Ferrer A, Uriarte I, et al. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 2008;134:1482-1493.